Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
20 studies found for:    reolysin
Show Display Options
Rank Status Study
1 Recruiting Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Condition: KRAS Mutant Metastatic Colorectal Cancer
Interventions: Biological: REOLYSIN®;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Fluorouracil (5-FU);   Drug: Bevacizumab
2 Completed Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
3 Completed Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Conditions: Osteosarcoma;   Ewing Sarcoma Family Tumors;   Malignant Fibrous Histiocytoma;   Sarcoma, Synovial;   Fibrosarcoma;   Leiomyosarcoma
Intervention: Biological: REOLYSIN®
4 Recruiting Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel, Reolysin and Prednisone;   Drug: Docetaxel and Prednisone
5 Recruiting Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed and Reolysin (and safety run-in);   Drug: Pemetrexed;   Drug: Docetaxel and Reolysin;   Drug: Docetaxel
6 Active, not recruiting Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Condition: Carcinoma, Non-small Cell Lung
Interventions: Biological: REOLYSIN®;   Drug: Carboplatin;   Drug: Paclitaxel
7 Completed Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Condition: Malignant Glioma
Intervention: Biological: REOLYSIN®
8 Recruiting A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Reolysin
9 Recruiting Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Folfox plus Bevacizumab and reolysin;   Drug: Folfox plus Bevacizumab
10 Unknown  A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Biological: REOLYSIN;   Drug: Gemcitabine
11 Completed Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel
12 Active, not recruiting A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Condition: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Interventions: Biological: REOLYSIN;   Drug: Paclitaxel;   Drug: Carboplatin
13 Completed Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN®;   Drug: Carboplatin;   Drug: Paclitaxel
14 Completed
Has Results
Viral Therapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Intervention: Biological: wild-type reovirus
15 Active, not recruiting Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Refractory Plasma Cell Myeloma
Interventions: Biological: Wild-type Reovirus;   Other: Diagnostic Laboratory Biomarker Analysis
16 Recruiting Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma
Condition: Refractory Plasma Cell Myeloma
Interventions: Drug: Dexamethasone;   Drug: Carfilzomib;   Biological: Wild-type Reovirus;   Other: Laboratory Biomarker Analysis
17 Active, not recruiting Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Wild-type Reovirus;   Other: Laboratory Biomarker Analysis
18 Active, not recruiting Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Biological: Wild-type Reovirus;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Laboratory Biomarker Analysis
19 Active, not recruiting Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Wild-type Reovirus;   Drug: Paclitaxel
20 Completed Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Other: pharmacological study

Indicates status has not been verified in more than two years